BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Eli Lilly Price Target Maintained With a $885.00/Share by Cantor Fitzgerald
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly Analyst Ratings
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,030
HSBC Adjusts Price Target on Eli Lilly and Co. to $1,150 From $1,100, Maintains Buy Rating
Eli Lilly Analyst Ratings
Daiwa Securities Adjusts Price Target on Eli Lilly and Co. to $940 From $800, Maintains Outperform Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,050
Berenberg Bank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,060
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Why Eli Lilly Is a Buy After Earnings. The Stock Got an Upgrade. -- Barrons.com
Eli Lilly Analyst Ratings
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly Price Target Raised to $1000.00/Share From $875.00 by Wells Fargo
Eli Lilly & Co: A Balanced Hold Rating Amid Growth and Competitive Challenges
Redburn Atlantic Adjusts Eli Lilly Price Target to $640 From $600